• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bone Biologics Corp - warrants (NQ:BBLGW)

    9.530 UNCHANGED
    Streaming Delayed Price Updated: 2:30 PM EDT, Jul 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 9.530
    Bid (Size) 8.010 (100)
    Ask (Size) 14.00 (1,300)
    Prev. Close 9.530
    Today's Range 9.530 - 9.530
    52wk Range 6.800 - 35.95
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
    Strengthened capital position supports continued advancement of NB1 clinical development, manufacturing readiness and intellectual property initiatives through Q2 2027 
    From BONE BIOLOGICS CORPORATION
    Via GlobeNewswire
    News headline image
    Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
    $3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants in cash 
    From BONE BIOLOGICS CORPORATION
    Via GlobeNewswire

    Performance

    YTD
    -35.2%
    -35.2%
    1 Month
    +19.1%
    +19.1%
    3 Month
    -52.3%
    -52.3%
    6 Month
    -44.1%
    -44.1%
    1 Year
    -11.7%
    -11.7%

    More News

    Read More
    News headline image
    Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1
    From BONE BIOLOGICS CORPORATION
    Via GlobeNewswire
    News headline image
    Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
    From BONE BIOLOGICS CORPORATION
    Via GlobeNewswire
    News headline image
    Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
    From BONE BIOLOGICS CORPORATION
    Via GlobeNewswire
    News headline image
    Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Announces Closing of $5.0 Million Public Offering
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Announces Pricing of $5.0 Million Public Offering
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Files Patent Application for Bone Regeneration Technology
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Announces 1-for-6 Reverse Stock Split
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Appoints Phillip T. Meikle to its Board of Directors
    From Bone Biologics
    Via Business Wire
    News headline image
    Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Executives to be Interviewed in a “CEO Chat” by Zacks Small-Cap Research Analyst on June 20th
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
    From Bone Biologics Corporation
    Via Business Wire
    News headline image
    Bone Biologics Announces 1-for-8 Reverse Stock Split
    From Bone Biologics Corporation
    Via Business Wire

    Frequently Asked Questions

    Is Bone Biologics Corp - warrants publicly traded?
    Yes, Bone Biologics Corp - warrants is publicly traded.
    What exchange does Bone Biologics Corp - warrants trade on?
    Bone Biologics Corp - warrants trades on the Nasdaq Stock Market
    What is the ticker symbol for Bone Biologics Corp - warrants?
    The ticker symbol for Bone Biologics Corp - warrants is BBLGW on the Nasdaq Stock Market
    What is the current price of Bone Biologics Corp - warrants?
    The current price of Bone Biologics Corp - warrants is 9.530
    When was Bone Biologics Corp - warrants last traded?
    The last trade of Bone Biologics Corp - warrants was at 07/23/26 02:30 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.